Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: Results from the KEYNOTE-028 study

Patrick A. Ott, Yung Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J. Pishvaian, Hope S. Rugo, Igor Puzanov, Janice M. Mehnert, Kyaw L. Aung, Juanita Lopez, Marion Carrigan, Sanatan Saraf, Mei Chen, Jean Charles Soria

Research output: Contribution to journalArticlepeer-review

179 Scopus citations


Purpose: The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti–programmed death 1 monoclonal antibody, in patients with programmed death ligand 1 (PD-L1)–positive advanced solid tumors. The results from the advanced endometrial cancer cohort are reported. Patients and Methods: Female patients with locally advanced or metastatic PD-L1–positive endometrial cancer who had experienced progression after standard therapy were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks for up to 24 months or until progression or unacceptable toxicity. Primary efficacy end point was objective response rate by RECIST (version 1.1). Secondary end points included safety, duration of response (DOR), progression-free survival, and overall survival. The data cutoff was February 17, 2016. Results: Of 75 patients screened, 36 (48.0%) had PD-L1–positive tumors, and 24 (32.0%) were enrolled. Fifteen (62.5%) of these 24 patients had received at least two previous lines of therapy for advanced disease. Three patients (13.0%) achieved confirmed partial response (95% CI, 2.8% to 33.6%); the median DOR was not reached. Two patients were still receiving treatment and exhibiting continued response at time of data cutoff. Three additional patients (13.0%) achieved stable disease, with a median duration of 24.6 weeks. One patient who achieved partial response had a polymerase E mutation. Thirteen patients (54.2%) experienced treatment-related adverse events (AEs), with fatigue (20.8%), pruritus (16.7%), pyrexia (12.5%), and decreased appetite (12.5%) occurring in ≥ 10% of patients. Grade 3 treatment-related AEs were reported in four patients. No patient experienced a grade 4 AE, and no patient discontinued treatment because of an AE. Conclusion: Pembrolizumab demonstrated a favorable safety profile and durable antitumor activity in a subgroup of patients with heavily pretreated advanced PD-L1–positive endometrial cancer.

Original languageEnglish (US)
Pages (from-to)2535-2541
Number of pages7
JournalJournal of Clinical Oncology
Issue number22
StatePublished - Aug 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: Results from the KEYNOTE-028 study'. Together they form a unique fingerprint.

Cite this